Chen, Chieh-I

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: A multicentre, open-label, global, phase 3, randomised, controlled trial

Sezer, A., Kilickap, S., Gümüş, M., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., Turk, H. M., Cicin, I., Bentsion, D., Gladkov, O., et al. (2021) · The Lancet

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 789

Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma

Keeping, S., Xu, Y., Chen, C.-I., Cope, S., Mojebi, A., Kuznik, A., Konidaris, G., Ayers, D., Sasane, M., Allen, R., et al. (2021) · Future Oncology

Nonmelanoma Skin Cancer StudiesCancer Immunotherapy and Biomarkers

Cited by 51